Status | Study |
Recruiting |
Study Name: A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Condition: Cancer Ovaries Cancer Peritoneal Cancer, Fallopian Tube Date: 2017-01-13 Interventions: Drug: OMP-305B83 intravenous ( |
Recruiting |
Study Name: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2016-09-12 Interventions: Drug: Part A: Dose Escalation of Cantrixil |
Not yet recruiting |
Study Name: DNA Single Nucleotide Polymorphisms as Predictors of Toxicity Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2015-06-16 |
Recruiting |
Study Name: Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study Condition: Malignant Neoplasm of Fallopian Tube Date: 2015-01-10 Interventions: Other: PCR for chlamydia DNA in primary tubal cancer PCR for presence of chlamydia DNA in paraffin block |
Recruiting |
Study Name: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Condition: Ovarian Neoplasms Peritoneal Neoplasms Date: 2013-05-01 Interventions: Drug: Trabectedin 1.1 mg/m2 ad |
Withdrawn |
Study Name: 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant Condition: Ovarian Neoplasms Ovarian Cancer Fal Date: 2013-01-10 Interventions: Drug: [18F]-CP18 7mCi, IV (in |
Terminated |
Study Name: Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer Condition: Epithelial Ovarian Cancer Peritoneal Neoplasms Date: 2012-09-05 Interventions: Drug: Birinapant (TL32711) 47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle |
Completed |
Study Name: Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2011-03-09 Interventions: Drug: Pegylated L-Asparaginase Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks |
Terminated |
Study Name: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer Condition: Neoplasms Ovarian Neoplasms Fallopia Date: 2011-01-11 Interventions: Biological: KHK2866 Potentiall |
Withdrawn |
Study Name: A Prospective Trial of COXEN Chemotherapy Prediction Condition: Ovarian Neoplasms Fallopian Tube Neoplasms Date: 2010-10-20 Interventions: Device: COXEN analysis for chemotherapy prediction Using the affymetrix genechip along with the COXEN al |